Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCL NASDAQ:ADMA NASDAQ:CRSP NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$3.99-1.5%$4.28$1.89▼$5.82$1.19B0.645.00 million shs4.24 million shsADMAADMA Biologics$16.90-1.7%$17.74$13.50▼$25.67$4.03B0.543.13 million shs5.81 million shsCRSPCRISPR Therapeutics$52.98+0.6%$55.98$30.04▼$71.13$4.82B1.812.56 million shs1.64 million shsRYTMRhythm Pharmaceuticals$101.69-2.4%$87.59$45.00▼$106.52$6.75B2.23661,192 shs621,711 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics-3.11%-7.32%-4.48%+67.36%+58.20%ADMAADMA Biologics-0.35%+0.58%-11.02%-15.40%-0.64%CRSPCRISPR Therapeutics+1.60%-4.05%-6.12%+38.40%+10.35%RYTMRhythm Pharmaceuticals+1.03%+2.97%+18.02%+61.84%+120.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCLAbCellera Biologics2.308 of 5 stars3.51.00.00.02.43.30.0ADMAADMA Biologics4.0075 of 5 stars3.71.00.00.03.72.53.1CRSPCRISPR Therapeutics3.5943 of 5 stars4.22.00.00.02.93.30.6RYTMRhythm Pharmaceuticals3.2973 of 5 stars2.51.00.04.33.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 3.00Buy$8.00100.50% UpsideADMAADMA Biologics 3.33Buy$27.6763.71% UpsideCRSPCRISPR Therapeutics 2.47Hold$71.6035.15% UpsideRYTMRhythm Pharmaceuticals 3.07Buy$101.57-0.12% DownsideCurrent Analyst Ratings BreakdownLatest ABCL, CRSP, ADMA, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025CRSPCRISPR TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/8/2025ABCLAbCellera BiologicsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.008/7/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$65.00 ➝ $80.008/7/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$80.00 ➝ $100.008/6/2025CRSPCRISPR TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$42.00 ➝ $56.008/6/2025RYTMRhythm PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$119.00 ➝ $120.008/6/2025RYTMRhythm PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$130.00 ➝ $135.008/5/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$100.00 ➝ $109.008/5/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.008/5/2025CRSPCRISPR TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$38.00 ➝ $42.007/22/2025CRSPCRISPR TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$79.00 ➝ $78.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$28.83M41.36N/AN/A$3.37 per share1.18ADMAADMA Biologics$474.17M8.51$0.53 per share31.89$1.67 per share10.12CRSPCRISPR Therapeutics$35M137.67N/AN/A$18.81 per share2.82RYTMRhythm Pharmaceuticals$156.29M43.22N/AN/A($0.18) per share-564.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$162.86M-$0.55N/AN/AN/A-511.88%-16.17%-12.24%11/3/2025 (Estimated)ADMAADMA Biologics$197.67M$0.8619.6524.49N/A44.06%41.01%28.47%11/6/2025 (Estimated)CRSPCRISPR Therapeutics-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%11/4/2025 (Estimated)Latest ABCL, CRSP, ADMA, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ABCLAbCellera Biologics-$0.17-$0.12+$0.05-$0.12$7.55 million$17.08 million8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 million8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 million8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AADMAADMA BiologicsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A11.0711.07ADMAADMA Biologics0.215.332.78CRSPCRISPR TherapeuticsN/A16.6116.61RYTMRhythm PharmaceuticalsN/A2.792.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%ADMAADMA Biologics75.68%CRSPCRISPR Therapeutics69.20%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%ADMAADMA Biologics3.70%CRSPCRISPR Therapeutics4.30%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.83 million212.47 millionOptionableADMAADMA Biologics530238.63 million229.80 millionOptionableCRSPCRISPR Therapeutics46090.95 million87.22 millionOptionableRYTMRhythm Pharmaceuticals14066.42 million62.37 millionOptionableABCL, CRSP, ADMA, and RYTM HeadlinesRecent News About These CompaniesPDT Partners LLC Purchases 58,612 Shares of Rhythm Pharmaceuticals, Inc. $RYTMSeptember 3 at 8:13 AM | marketbeat.comPanagora Asset Management Inc. Purchases Shares of 141,162 Rhythm Pharmaceuticals, Inc. $RYTMSeptember 3 at 5:53 AM | marketbeat.comNorthern Trust Corp Sells 9,108 Shares of Rhythm Pharmaceuticals, Inc. $RYTMSeptember 2 at 4:10 AM | marketbeat.comRafferty Asset Management LLC Acquires 7,338 Shares of Rhythm Pharmaceuticals, Inc. $RYTMSeptember 1 at 4:44 AM | marketbeat.comCitizens JMP Keeps Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)September 1 at 2:10 AM | insidermonkey.comCitizens JMP Keeps Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)September 1 at 2:33 AM | uk.finance.yahoo.comRhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by Driehaus Capital Management LLCAugust 31 at 7:14 AM | marketbeat.comSiren L.L.C. Acquires Shares of 277,533 Rhythm Pharmaceuticals, Inc. $RYTMAugust 31 at 6:29 AM | marketbeat.comJump Financial LLC Invests $2.21 Million in Rhythm Pharmaceuticals, Inc. $RYTMAugust 30, 2025 | marketbeat.comAlphaQuest LLC Has $350,000 Stock Position in Rhythm Pharmaceuticals, Inc. $RYTMAugust 30, 2025 | marketbeat.comComerica Bank Increases Position in Rhythm Pharmaceuticals, Inc. $RYTMAugust 29, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. $RYTM Shares Purchased by Price T Rowe Associates Inc. MDAugust 29, 2025 | marketbeat.comFDA Accepts a New Drug Application From Rhythm Pharmaceuticals (RYTM)August 29, 2025 | finance.yahoo.comBrokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $101.57August 29, 2025 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Recommendation of "Buy" from BrokeragesAugust 28, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells $419,093.16 in StockAugust 27, 2025 | marketbeat.comRhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comNuveen LLC Makes New $7.80 Million Investment in Rhythm Pharmaceuticals, Inc. $RYTMAugust 27, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Insider Joseph Shulman Sells 4,188 SharesAugust 26, 2025 | americanbankingnews.comInsider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells 4,188 Shares of StockAugust 26, 2025 | insidertrades.comInvesco Ltd. Lowers Holdings in Rhythm Pharmaceuticals, Inc. $RYTMAugust 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Vertical Aerospace: An Analyst's Roadmap to a Potential Re-RatingBy Jeffrey Neal Johnson | August 27, 2025The Uber Eats Partnership Fueling Serve Robotics' GrowthBy Jeffrey Neal Johnson | August 28, 2025ABCL, CRSP, ADMA, and RYTM Company DescriptionsAbCellera Biologics NASDAQ:ABCL$3.99 -0.06 (-1.48%) Closing price 04:00 PM EasternExtended Trading$4.01 +0.02 (+0.63%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.ADMA Biologics NASDAQ:ADMA$16.90 -0.30 (-1.74%) Closing price 04:00 PM EasternExtended Trading$16.98 +0.08 (+0.44%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.CRISPR Therapeutics NASDAQ:CRSP$52.98 +0.32 (+0.61%) Closing price 04:00 PM EasternExtended Trading$53.25 +0.27 (+0.51%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Rhythm Pharmaceuticals NASDAQ:RYTM$101.69 -2.52 (-2.42%) Closing price 04:00 PM EasternExtended Trading$99.00 -2.69 (-2.65%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
